Partial
Partially Aligned
Patient Risk:
Low
Summary
The provided response content evaluates label support for neutropenia/diarrhea and is broadly consistent with the supplied label sections, but it includes substantial unsupported/extra mechanistic and intended-benefit statements that are not supported by the cited label excerpts.
Category Scores
Accurate Statements
ONIVYDE can cause severe or life-threatening neutropenia, including fatal neutropenic sepsis and fatal neutropenic fever.
Boxed Warning; Section 5.1 Severe Neutropenia
Monitor complete blood cell counts on Days 1 and 8 of every cycle; withhold ONIVYDE if ANC <1500/mm^3 or if neutropenic fever occurs; resume when ANC ≥1500/mm^3.
Section 5.1 Severe Neutropenia; Boxed Warning; Section 2.2
ONIVYDE can cause severe and life-threatening diarrhea; do not administer to patients with bowel obstruction.
Boxed Warning; Section 5.2 Severe Diarrhea
Withhold ONIVYDE for Grade 2-4 diarrhea.
Boxed Warning; Section 5.2 Severe Diarrhea
Administer atropine 0.25 to 1 mg for early onset diarrhea of any severity (unless contraindicated) and initiate loperamide for late onset diarrhea of any severity.
Section 5.2 Severe Diarrhea; Boxed Warning
Resume ONIVYDE following recovery to Grade 1 diarrhea at a reduced dose.
Section 5.2 Severe Diarrhea
The provided safety claim is supported by the supplied label sections.
Sections 5.1/5.2 and Boxed Warning as supplied
Unsupported Statements
Onivyde is a liposomal formulation of irinotecan.
Not supported by the supplied label excerpts (only ONIVYDE/irinotecan safety management sections were provided).
Irinotecan in Onivyde is a topoisomerase I inhibitor.
Not supported by the supplied label excerpts.
Altering irinotecan's pharmacokinetic profile is intended to potentially improve efficacy and manage toxicity; intended to enhance delivery to tumor sites; intended to reduce exposure to healthy tissues; intended to control release of the active drug.
These stated intentions/desired effects are not supported by the supplied label excerpts.
Irinotecan works by inhibiting topoisomerase I; DNA damage ultimately leads to cancer cell death.
Mechanism details are not supported by the supplied label excerpts.
Onivyde is intended to potentially mitigate some side effects.
Not supported by the supplied label excerpts.
Careful monitoring by a healthcare professional is necessary when using Onivyde.
While monitoring is supported for CBC/ANC and diarrhea management in the provided sections, the broad statement about monitoring necessity is not specifically supported as a general claim in the supplied excerpts.
Contradictions
Important Omissions
The evaluation does not explicitly address label wording differences such as diarrhea patterns (early vs late) details beyond management and may not reflect the specific early/late timing language throughout the broader statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The core evaluated safety management claims for neutropenia and diarrhea are aligned with the supplied label sections, but additional unsupported mechanistic/intended-benefit statements reduce label-faithfulness without introducing direct dosing contradictions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Includes multiple mechanistic and intended-effect statements not supported by the supplied FDA label excerpts.
Suggested Improvement
Limit claims to the specific supported label content provided (e.g., boxed warning, Sections 5.1/5.2, and related dosing/monitoring instructions) and remove or qualify liposomal/topoisomerase/pharmacokinetic-intent mechanistic statements unless the full label text supporting them is supplied.